Among all cancer patients, the prevalence and mortality rate of lung cancer are the highest. The treatment of lung cancer is relatively difficult. In the past, there was only one method of surgery. Now, after decades of development, many scientific researchers and pharmaceutical companies have unremitting efforts and investment, and new methods for targeted drugs for the treatment of cancer have been developed. Compared with the original radiotherapy and chemotherapy, targeted drugs can accurately find and kill cancer cells, and will not have a great impact on the good cells in the original body and reduce the side effects on the body. However, the cost of drug research and development is very high. The circulating three 10-year theory takes 10 years, a 1 billion yuan investment, and a 10% success rate. Therefore, after the drug is developed, it will increase the selling price during the patent protection period to make a profit. Due to the basic principles of insurance, medical insurance will fully consider the annual treatment price of drugs when formulating medical insurance catalogs. The annual treatment price of drugs that were first launched is relatively high, and many of them are not included in the medical insurance reimbursement scope.
In recent years, due to the expiration of some drug patents, the launch of generic drugs, and the impact of volume-based procurement by the State Health Insurance Administration, some targeted drugs for treating lung cancer have been included in the reimbursement scope of medical insurance through negotiations. However, even if the price of centralized procurement is reduced, the price of this kind of drug is still relatively high, so there are many restrictions. Many places need to use it and additional applications are required. Let’s take a look at the restrictions and reimbursement amounts of common targeted drugs used in lung cancer!
Bevacizumab : Advanced, metastatic or recurrent non-small cell lung cancer: Bevacizumab combined with platinum-based chemotherapy is used for first-line treatment in patients with unresectable advanced, metastatic or recurrent non-squamous cell non-small cell lung cancer : locally advanced or metastatic non-small cell lung cancer patients with anaplastic lymphoma kinase (ALK) positive or advanced non-small cell lung cancer patients with ROS1 positive.
seretinib capsule : Treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) positive for anaplastic lymphoma kinase (ALK).
Aletinib hydrochloride capsules: A locally advanced or metastatic non-small cell lung cancer patients with anaplastic lymphoma kinase (ALK).
These four drugs have many restrictions, and the other restrictions are similar.
also includes the following lung cancer targeted drugs reimbursed by medical insurance: Xindilizumab injection, tirelizumab injection, and Carreli for injection Vizumab, osimertinib methanesulfonate tablets, ametinib methanesulfonate tablets, anlotinib hydrochloride capsules, crizotinib capsules, seretinib capsules, aletinib hydrochloride capsules, ensatinib hydrochloride capsules, vometinib methanesulfonate tablets, dacotinib tablets, ecretinib hydrochloride tablets, recombinant human vascular endostatin injection pemetrexed , bevacizumab, gefitinib, afatinib , erlotinib. These drugs are different. The most expensive one in is anlotinib: the resident medical insurance needs to be about 7,000 yuan after reimbursement, while the cheapest one is gefitinib: after reimbursement by medical insurance, you only need to travel about 100 yuan. If you need to use , you can use it as a reference.
Many places need to use these targeted drugs and require additional dual-channel drug use applications, because many hospital pharmacies are not equipped and need to go to designated pharmacies outside to purchase. After filling out the dual-channel drug application and use evaluation form in the hospital, you can purchase at the designated designated pharmacies and can also be reimbursed proportionally. Some doctors in major hospitals will find it troublesome and will not tell patients and their families about this policy. Those who need to use these drugs remember to ask about the local policies clearly and do not waste medical insurance reimbursement qualifications.
